Cassiopea has filed a New Drug Application seeking the FDA's approval for its topical androgen receptor inhibitor cream clascoterone as a first-in-class acne treatment. The filing is supported by data from two of the company's late-stage trials testing the clascoterone cream or a vehicle cream over a 12-week period.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.